LOXL2 Recombinant Monoclonal Antibody

Code CSB-RA907007A0HU
Size US$210
Order now
Image
  • Western Blot
    Positive WB detected in: MCF-7 whole cell lysate, PC3 whole cell lysate, Mouse brain tissue, Rat brain tissue
    All lanes: LOXL2 antibody at 1:2000
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 87 kDa
    Observed band size: 53 kDa
  • IHC image of CSB-RA907007A0HU diluted at 1:100 and staining in paraffin-embedded human prostate tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • IHC image of CSB-RA907007A0HU diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • Immunofluorescence staining of HepG2 Cells with CSB-RA907007A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
  • Overlay histogram showing A549 cells stained with CSB-RA907007A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then incubated in 10% normal goat serum to block non-specific protein-protein interactions followedby the antibody (1µg/1*106 cells) for 1 h at 4℃.The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 30min at 4℃. Control antibody (green line) was Rabbit IgG (1µg/1*106 cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
LOXL2
Alternative Names
Lysyl oxidase homolog 2 (EC 1.4.3.13) (Lysyl oxidase-like protein 2) (Lysyl oxidase-related protein 2) (Lysyl oxidase-related protein WS9-14), LOXL2
Species Reactivity
Human, Mouse, Rat
Immunogen
A synthesized peptide derived from human LOXL2
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
2E5
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, WB, IHC, IF, FC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
IF 1:20-1:200
FC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The DNA sequence coding for the LOXL2 monoclonal antibody produced from the animals with recombinant human LOXL2 immunization was cloned into the expression vector, which was further transfected into a cell line for in vitro expression. The product is the recombinant LOXL2 monoclonal antibody. It specifically recognizes and detects the LOXL2 from human, mouse, and rat samples. It belongs to the rabbit IgG. The affinity-chromatography purification method was used to purify this LOXL2 antibody. This LOXL2 antibody has been validated for use in ELISA, WB, IHC, IF, and FC analyses.

Similar to LOX, LOXL2 promotes the cross-linking of collagen and elastin in the extracellular matrix (ECM). LOXL2 is also involved in the regulation of signaling pathways inside or outside the cell. Disorders of LOXL2 lead to diverse diseases, such as fibrosis, heart disease, and cancer. The expression and function of LOXL2 in tumor progression vary among tissue types. Over-expression of LOXL2 promotes tumor metastasis.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription. LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3. During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription. SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits. Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction. Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression. When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.
Gene References into Functions
  1. although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis. PMID: 29953488
  2. we report that overexpression of LOXL2 promotes its accumulation in the Endoplasmic Reticulum where it interacts with HSPA5 leading to activation of the IRE1-XBP1 signalling pathway of the ER-stress response. PMID: 28332555
  3. Copper loading robustly activates hLOXL2 and supports lysyl tyrosylquinone formation. PMID: 29581294
  4. LOXL2 might have an important role in CRC. PMID: 29845296
  5. Results revealed that LOXL2 expression was higher in hepatocellular carcinoma (HCC) cell lines and tissues. There was a significant correlation between EMT status and LOXL2 levels indicated that a higher level of LOXL2 may contribute to tumor progression. PMID: 29620290
  6. Plasma LOXL2 was significantly elevated and also strongly correlated with the degree of left atrial fibrosis in Atrial fibrillation patients with normal left ventricular function. PMID: 29089463
  7. LOXL2 may be involved in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and might be helpful in early diagnosis of RA-ILD. PMID: 29052023
  8. Glomerular LOXL2 was localized to the cytoplasm of podocytes, as determined by double immunofluorescence microscopy using a podocyte marker (synaptopodin). This result was supported by western blot analysis, which demonstrated that LOXL2 protein expression is present in cultured human podocytes and HK2 human proximal tubular cells. PMID: 28677767
  9. Lysyl oxidase like-2 (LOXL2) overexpression differentially regulates signaling pathways in osteoarthritis chondrocytes. PMID: 28764769
  10. our data reveal that the tumor-promoting role of LOXL2 in ESCC is mediated by perturbing the architecture of actin cytoskeleton through its PPIs. PMID: 28556501
  11. HIF-1alpha plays an important role in the development of HCC by promoting HCC metastasis, EMT and VM through up-regulating LOXL2. PMID: 28449718
  12. Participants were evaluated as part of a clinical trial evaluating the safety and efficacy of simtuzumab a humanized monoclonal antibody that inhibits lysyl oxidase-like 2 (LOXL2), an enzyme that contributes to liver fibrosis by catalyzing collagen cross-linkage PMID: 28480218
  13. expression of LOXL2 endowed dormant tumor cells with cancer stem cell-like phenotype driving their transition to metastatic outgrowth and this stem-like phenotype is dependent on epithelial to mesenchymal transition (EMT) that can be driven by the tumor microenvironment. PMID: 27655685
  14. Simtuzumab is a humanized IgG4 monoclonal antibody that inhibits enzymatic activity of LOXL2... inhibition of LOXL2 expression reduced numbers of activated fibroblasts, decreased ECM deposition, inhibited angiogenesis, and prevented tumor cell invasion and metastases PMID: 28246206
  15. higher LOXL2 expression is associated with the invasiveness of pancreatic cancer cells and the low survival rate of pancreatic cancer patients PMID: 27285767
  16. LOXL2 c.C133T is a pathogenic mutation that is responsible for a fraction of familial intracranial aneurysms. PMID: 29107163
  17. data demonstrate that proteolytic processing is an important event that allows LOXL2-mediated crosslinking of basement membrane collagen IV. PMID: 28864775
  18. new LOXL2 splice variant contributes to tumor progression by novel molecular mechanisms different from LOXL2WT PMID: 27063404
  19. LOXL2 is a potential therapeutic target against tumor progression. PMID: 27694892
  20. Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. PMID: 28468951
  21. SMYD3 enhances tumorigenicity in esophageal squamous cell carcinoma by enhancing transcription of ezrin and LOXL2, which are involved in proliferation, migration, and invasion. PMID: 26980013
  22. Data show that lysyl oxidase-like 2 (LOXL2) is a histone modifier enzyme that removes trimethylated lysine 4 (K4) in histone H3 (H3K4me3) through an amino-oxidase reaction. PMID: 27735137
  23. LOXL2 was determined to promote proliferation of hepatocellular carcinoma (HCC) and demonstrated to be highly expressed in HCC adjacent non-tumor tissue samples compared with tumor tissue samples. PMID: 27430160
  24. LOXL2 messenger RNA levels were increased in intrahepatic cholangiocarcinoma. These results were confirmed at a protein level, with a significantly higher LOXL2 immunostaining tumoral stroma. Univariate analysis revealed that LOXL2 expression was correlated with a poor overall survival and disease-free survival. PMID: 27363654
  25. glomerular extracellular matrix. Altogether, we demonstrate that LOXL2 is a novel component of the molecular machinery that forms cross-linked collagen IV networks, which are essential for glomerular basement membrane stability and molecular ultrafiltration function. PMID: 27770022
  26. The expression levels of lysyl oxidase-like 2 (LOXL2) mRNA and protein were markedly suppressed in transfected prostate cancer cells with microRNAs miR-26a, miR-26b, miR-29a, miR-29b, miR-29c and miR-218. PMID: 27278788
  27. Overexpression of LOXL2 and SERPINH1 was observed in clinical specimens of lung cancer and fibrotic lesions. Downregulation of miR-29a caused overexpression of LOXL2 and SERPINH1 in lung cancer and IPF, suggesting that these genes are involved in the pathogenesis of these two diseases. PMID: 27488440
  28. LOXL2 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
  29. BMP2 and RUNX2 are expressed exclusively by osteoblasts whereas DSPP and LOXL2 are expressed exclusively by odontoblasts. (Review) PMID: 27784228
  30. Results showed that LOXL2 was overexpressed in head and neck squamous cell carcinoma clinical specimens and that silencing of the LOXL2 gene significantly inhibited the migration and invasion of cancer cells. PMID: 26490187
  31. ECM crosslinking by EC-derived exosomes is mediated by LOXL2. PMID: 26612622
  32. Results show that miR-26a and miR-26b were significantly downregulated in renal cell carcinoma clinical specimens and appeared to function as tumor suppressors through regulation of collagen cross-linking enzymes, LOXL2 and PLOD2, both of which function as oncogenes in this disease. PMID: 26983694
  33. Loss of tumor-suppressive miR29s enhanced cancer cell invasion in lung SCC through direct regulation of oncogenic LOXL2. PMID: 26676674
  34. LOXL2 promotes tumor progression. PMID: 26329904
  35. We identified LOXL2 to be associated with the outcome of colon cancer patients. Furthermore, it can be used to stratify patients at stages II and III for further therapeutic decisions. PMID: 26206869
  36. Data suggest that restoration of MIRN29 (microRNA 29) synthesis silences expression of LOXL2 (lysyl oxidase-like 2) and inhibits cell proliferation, migration, and invasiveness of renal cell carcinoma cells. PMID: 26096783
  37. Lysine oxidation of the transcription factor TAF10 by LOXL2 is a controlled protein modification and demonstrates a role for protein oxidation in regulating pluripotency genes. PMID: 25959397
  38. identified novel alternative splicing isoform, LOXL2 Deltae13; data suggest it modulates effects of cancer cell migration and invasion through a different mechanism from full-length LOXL2 and may play an important role in tumor carcinogenesis and progression PMID: 25275797
  39. The structure and functions of human lysyl oxidase-like 2 (LOXL2) are reviewed. [review] PMID: 25146937
  40. LOXL2 is a direct repressor of NOTCH1.There is an exclusive expression pattern between LOXL2 and members of the canonical NOTCH1 pathway in human head and neck squamous cell carcinoma. PMID: 25759215
  41. Data indicate potential roles of LOXL2 (lysyl oxidase-like 2) splice variants with large scale data. PMID: 25254241
  42. LOXL2 expression in stromal cells may be a useful prognostic factor for patients with gastric cancer. Fibroblast-derived LOXL2 may stimulate the motility of gastric cancer cells. PMID: 25128648
  43. LOXL2 activates the FAK/Akt/mTOR signaling pathways and promotes cell proliferation and inhibits apoptotic cell death. PMID: 24863880
  44. promoted intrahepatic metastasis by increasing tissue stiffness PMID: 25048396
  45. higher sLOXL2 levels are associated with increased risk for IPF disease progression PMID: 24177001
  46. These results provide important clues for experimental identification of the specific biological roles and molecular mechanisms of LOXL2-delta72. PMID: 24716982
  47. LOXL2 expression in normal epithelial cells can induce abnormal changes that resemble oncogenic transformation and cancer progression. PMID: 23971878
  48. Findings reveal new insight into the mechanisms of fibroblast activation, a novel function of LOXL2, and further highlight the importance of generating LOXL2-targeted therapies for the prevention of tumor progression and metastasis. PMID: 24008674
  49. Higher LOXL2 expression is associated with invasiveness of basal-like breast cancer cells and lower survival of breast cancer patients. PMID: 23933800
  50. Sequence analysis of LOXL2, genes did not reveal any putative mutations for hyperostosis cranialis interna to chromosome 8p21 PMID: 23640157

Show More

Hide All

Subcellular Location
Secreted, extracellular space, extracellular matrix, basement membrane. Nucleus. Chromosome. Endoplasmic reticulum.
Protein Families
Lysyl oxidase family
Tissue Specificity
Expressed in many tissues. Highest expression in reproductive tissues, placenta, uterus and prostate. In esophageal epithelium, expressed in the basal, prickle and granular cell layers. Up-regulated in a number of cancers cells and tissues.
Database Links

HGNC: 6666

OMIM: 606663

KEGG: hsa:4017

STRING: 9606.ENSP00000373783

UniGene: Hs.626637

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*